Serum dehydroepiandrosterone sulphate levels in patients with non-alcoholic fatty liver disease

Internal Medicine

Volumn 50, Issue 16, 2011, Pages 1657-1661

  Koga, Masafumi ^a   Saito, Hiroshi ^a   Mukai, Mikio ^a   Saibara, Toshiji ^b   Kasayama, Soji ^c  

^a KINKI CENTRAL HOSPITAL   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c NISSAY HOSPITAL   (Japan)

Author keywords

Alanine aminotransferase; Dehydroepiandrosterone; Fatty liver; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; INSULIN; LIPID; PRASTERONE SULFATE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; ECHOTOMOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPANESE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS HEPATITIS;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; DEHYDROEPIANDROSTERONE SULFATE; FATTY LIVER; HUMANS; MALE; MIDDLE AGED;

EID: 84860411907     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4682     Document Type: Article

References (31)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2 Suppl 1): S99-S112, 2006.
2. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134-140, 2002.
3. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113-121, 2005.
4. Anguro O. Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
5. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122: 274-280, 2002.
6. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54: 117-121, 2005.
7. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125: 1796-1807, 2003.
8. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50: page typefirst1844/pagex-/xpage typelast 1850/page, 2001.
9. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120: 1183-1192, 2001.
10. Techernof A, Labrie F. Dehydroepiandrosterone, obesity, and cardiovascular disease risk: a review of human studies. Europ J Endocrinol 151: 1-14, 2004.
11. Yanase T. Physiological significance of replacement therapy of dehydroepiandrosterone. Intern Med 43: 156-158, 2004.
12. Charlton M, Angulo P, Chalasani N, et al. Low circulating of dehydroepiandrosterone in histological advanced nonalcoholic fatty liver disease. Hepatology 47: 484-492, 2008.
13. Sumida Y, Yonei Y, Kanemasa K, et al. Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 40: 901-910, 2010.
14. Kasayama S, Morita S, Otsuki M, et al. Independent association of insulin-like growth factor-I with dehydroepiandrosterone sulphate in women in middle adulthood. Clin Endocrinol 22: 1701- 1706, 2005.
15. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21: 2191-2192, 1998.
16. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745-750, 2002.
17. Laughlin GA, Barrett-Connor E. Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: the Rancho Bernardo Study. J Clin Endocrinol Metab 85: 3561-3568, 2000.
18. Elekima OT, Mills CO, Ahmad A, et al. Reduced hepatic content of dehydroepiandrosterone sulphotransferase in chronic liver diseases. Liver 20: 45-50, 2000.
19. Yoneda M, Wada K, Katayama K, et al. A novel therapy for acute hepatitis utilizing dehydroepiandrosterone in the murine model of hepatitis. Biochem Pharmacol 68: 2283-2289, 2004.
20. Japan Society of Hepatology. Epidemiology of NAFLD. In: A Guidance for Clinicians on NASH/NAFLD. 2nd ed. Bunkodo, Tokyo, 2010 (in Japanese).
21. Ladriere L, Laghmich A, Malaisse-Lagae F, Malaisse WJ. Effect of dehydroepiandrosterone in hereditary diabetic rats. Cell Biochem Funct 15: 287-292, 1997.
22. Kimura M, Tanaka S, Yamada Y, Kikuchi Y, Yamakawa T, Sekihara H. Dehydroepiandrosterone decreases serum TNFα and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endocrinology 139: 3249-3253, 1998.
23. Mukasa K, Kaneshiro M, Aoki K, et al. Dehydroepiandrosterone (DHEA) ameliorates the insulin sensitivity in older rats. J Steroid Biochem Mol Biol 67: 355-358, 1998.
24. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endcrinol Metab 88: 3190-3195, 2003.
25. Yamashita R, Saito T, Satoh S, Aoki K, Kaburagi Y, Sekihara H. Effect of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocr J 52: 727-733, 2005.
26. Apostolova G, Schweizer RAS, Balazs Z, Kostadinova RM, Odermatt A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 288: E957-E964, 2005.
27. Stadeep TC, Walker BR. Pathophysiology of modulation of local glucocorticoid levels by 11β-hydroxysteroid dehydrogenase. Trends Endocrinol Metab 12: 446-453, 2001.
28. Stewart PM, Krozowski ZS. 11 beta-hydroxysteroid dehydrogenase. Vitam Horm 57: 249-324, 1999.
29. O'Malley BW. Results of a search for the mechanisms of steroid receptor regulation of gene expression. Ann NY Acad Sci 1038: 80-87, 2004.
30. Okabe T, Haji M, Takayanagi R, et al. Up-regulation of high affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 80: 2993-2996, 1995.
31. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277: 21379-21388, 2002.